1 day Ago By ABMN Staff
BridgeBio Pharma ( NASDAQ:BBIO – Get Free Report ) ‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $70.00 price target on the stock.
Cantor Fitzgerald’s price target suggests a potential upside of 161.88% from the stock’s current price. A number of other equities research analysts have also recently issued reports on BBIO.
JPMorgan Chase & Co. cut their target price on BridgeBio Pharma from $46.00 to $43.
00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. Piper Sandler started coverage on shares of BridgeBio Pharma in a research note on Wednesday, September 4th. They set an “overweight” rating and a $46.
00 target price on the stock. Bank of America reaffirmed a “buy” rating and issued a $42.00 price target on shares of BridgeBio Pharma in a research note on Wednesday, September 11th.
Evercore ISI lowered their price objective on shares of BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th.
Finally, HC Wainwright restated a “buy” rating and issued a $43.00 target price on shares of BridgeBio Pharma in a research report on Monday. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock.
According to MarketBeat, BridgeBio Pharma presently has an average rating of “Moderate Buy” and an average price target of $47.92. Read Our Latest Research Report on BBIO BridgeBio Pharma Price Performance BridgeBio Pharma ( NASDAQ:BBIO – Get Free Report ) last released its quarterly earnings results on Thursday, August 1st.
The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.
61. The business had revenue of $2.17 million during the quarter, compared to analyst estimates of $3.
96 million. The company’s revenue was up 32.1% compared to the same quarter last year.
During the same quarter last year, the firm posted ($0.98) EPS. On average, sell-side analysts anticipate that BridgeBio Pharma will post -2.
49 EPS for the current year. Insider Buying and Selling at BridgeBio Pharma In other news, major shareholder Genetic Disorder L.P.
Kkr sold 5,800,000 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $25.75, for a total value of $149,350,000.
00. Following the completion of the transaction, the insider now owns 25,260,971 shares of the company’s stock, valued at $650,470,003.25.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link . In other news, CFO Brian C. Stephenson sold 4,155 shares of the business’s stock in a transaction that occurred on Monday, August 19th.
The shares were sold at an average price of $24.69, for a total value of $102,586.95.
Following the transaction, the chief financial officer now owns 85,192 shares in the company, valued at approximately $2,103,390.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website .
Also, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of BridgeBio Pharma stock in a transaction dated Friday, September 13th.
The stock was sold at an average price of $25.75, for a total value of $149,350,000.00.
Following the completion of the transaction, the insider now directly owns 25,260,971 shares of the company’s stock, valued at $650,470,003.25. The disclosure for this sale can be found here .
Over the last three months, insiders sold 5,831,544 shares of company stock worth $150,128,821. 24.66% of the stock is currently owned by insiders.
Institutional Inflows and Outflows A number of institutional investors have recently added to or reduced their stakes in the company. Bfsg LLC lifted its stake in shares of BridgeBio Pharma by 175.6% in the second quarter.
Bfsg LLC now owns 1,240 shares of the company’s stock valued at $31,000 after buying an additional 790 shares in the last quarter. YHB Investment Advisors Inc. bought a new position in BridgeBio Pharma in the 1st quarter valued at about $34,000.
Headlands Technologies LLC acquired a new position in BridgeBio Pharma during the 2nd quarter valued at about $48,000. Quarry LP acquired a new position in BridgeBio Pharma during the 4th quarter valued at about $50,000. Finally, EntryPoint Capital LLC bought a new stake in BridgeBio Pharma during the 1st quarter worth approximately $117,000.
99.85% of the stock is owned by institutional investors and hedge funds. About BridgeBio Pharma ( Get Free Report ) BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. Read More Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter .
.
